Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer

NCT07283198 is registered in ClinicalTrials.gov with Jiangsu Alphamab Biopharmaceuticals Co., Ltd as lead sponsor.

NCT NCT07283198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07283198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer
Lead sponsor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 10, 2025
Completion date
August 30, 2027
Enrollment
160 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer (nsclc)